icon-folder.gif   Conference Reports for NATAP  
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
Sustained Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-7009), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days
  Reported by Jules Levin
AASLD Nov 2 2010 Boston
Michael P. Manns1, Edward Gane2, Maribel Rodriguez-Torres3, Albrecht Stoehr4, Chau-Ting Yeh5, Patrick Marcellin6, Richard Wiedmann7, Peggy M. Hwang8, Richard J.O. Barnard9, and Andrew W. Lee7,* *for the MK-7009 Protocol 007 Study Group 1Medical School of Hannover, Germany, 2Auckland Clinical Studies, New Zealand, 3Fundacion de Investigacion de Diego, and Ponce School of Medicine, Puerto Rico, 4 ifi-institute for interdisciplinary medicine, Hamburg, Germany, 5Liver Research Unit, Chang Gung Medical Center, Taipei, Taiwan, 6Service d'Hepatologie, Hopital Beaujon, Clichy, France, 7 ID/Vaccines Clinical Research, 8 Biostatistics, and 9Antiviral Research, Merck Research Laboratories, North Wales and 9West